For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Thank you for the added information. I have forwarded it to the customer and he is essentially a bit happier with the feedback. However, he is questioning your comment re the change in epitope specificity of a monoclonal.
I must say I was also unaware of that, so a reference that backs up that statement (as requested by the customer) would be useful, thanks.
Feedback from customer:
Somewhat better.. I was unaware that different preparations of the hybridoma alter the epitope specificity..would you be able to send me a reference to this for interest..
Asked on Nov 30 2012
Thanks you for your email. Apologies for delay.
This paper talks about how non producing cells can overtake a population and how it can potentially be resolved. It also mentions in the introduction how these changes may be due to mutation/loss of genes and cites some further references that may be useful.
These changes are likely to be what brings about lab-to-lab differences in productions of the same clone, particularly as the number of independent productions increases ie. The first production at each lab from a batch of identical cells received from the licensor is likely to be comparable but several productions later each lab may have slightly different populations of cells due to generally random nature of mutations/cell changes. Differences could potentially be further enhanced via subcloning and selection of a specific clone with enhanced traits (e.g. better secretion, better staining in IHC etc) for future productions.
I hope this infromaiton will be helpful.
Answered on Nov 30 2012